Bimekizumab (another anti-IL-17 agent) is also undergoing phase III clinical trials and is about as effective as secukinamub in terms of its clinical response rates going beyond 70% after 12 weeks. However, bimekizumab can reduce two types of interleukins (IL-17A and IL-17F), while secukinumab will only reduce IL-17A levels. This dual inhibitory effect makes bimekizunab seem more promising for HS treatment, and it consistently outperforms any placebo group outcome. The gene discussed is IL17A; the disease is histiocytic sarcoma.